Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured Series A financing to scale its drug discovery platform and biopharmaceutical partnerships.

Red Cell Partners led the financing, which included investments from Microsoft's M12, Madrona Venture Group, Third Kind Venture Capital, Dynamk Capital, and Empire State Development's venture capital arm, New York Ventures.